Chicago Atlantic Real Estate Finance, Inc. (REFI) Earnings Call Transcript & Summary

August 9, 2022

NASDAQ US Real Estate Mortgage Real Estate Investment Trusts (REITs) earnings 25 min

Earnings Call Speaker Segments

Tripp Sullivan

executive
#1

Thanks so much, and good morning to everyone. It's great to have you join us on the Chicago Atlantic Real Estate Finance Conference Call, where we'll be walking through the company's results for the second quarter of 2022. Joining us today are John Mazarakis, our Executive Chairman; Tony Cappell, our Chief Executive Officer; Andreas Bodmeier, Co-President and Chief Investment Officer; and Lindsay Menze, our Chief Financial Officer. This morning, we put out our results in the earnings press release, which you can locate in the investor relations section of our website, together with our supplemental filing with the SEC. A live audio webcast of today's call is available. If you happen to be listening to the replay of this webcast, please keep in mind that everything we say here reflects our remarks as of today, August 9, 2022, and nothing will be updated after this call. Throughout this call, some of the comments and statements we make might be considered forward-looking statements under the meaning prescribed by the securities law, including statements about the future performance of our portfolio, our pipeline of potential loans and other investments, future dividends, and financing activities. Every forward-looking statement reflects Chicago Atlantic's judgment as of the date of this conference call and carries risks and uncertainties that could cause actual results to differ materially from what we currently expect. We encourage investors to carefully review the various disclosures the company has made, including the risk and other information disclosed in the company's filings with the SEC. We'll also be discussing certain non-GAAP measures, including, but not limited to, distributable earnings and adjusted distributable earnings. You can find definitions of these non-GAAP measures and reconciliations to the most comparable GAAP measures in our filings with the SEC. At this point, I'll hand the call over to John Mazarakis. Please go ahead.

John Mazarakis

executive
#2

Thank you, Tripp. Good morning to all of you, and I appreciate you being here. Today presents what you could call a tale of two very different cities. On one side, we see solid fundamentals across the states we target and inside our portfolio. On the other side, the condition of the equity markets and the financing markets broadly is revealing weakness. We've devoted considerable effort to shaping the correct viewpoint in conversations regarding what this industry can achieve in terms of growth, how it runs counter to economic cycles, and the way it behaves similarly to pharma, liquor, and cigarette businesses. Betting on vertically integrated operators in limited license states, from where we stand, beats by a wide margin attempting to guess who wins and who loses in saturated markets where pricing gets crushed and thinner operators see their margins wiped out. Everything we've gone through up to now confirms each conviction we've ever held regarding this sector and its capacity to deliver. Tony will point out shortly that activity across our platform has never been higher. Emerging markets including New Jersey, New York, Ohio, and additional ones are steadily issuing more licenses and generating fresh demand. The operators we work with remain healthy, carrying reduced leverage and nothing else on their capital structure besides our debt; they've placed their business growth in our hands, and Chicago Atlantic will remain alongside them over the long haul. Those involved in private markets and throughout the industry recognize the genuine value being generated; meanwhile, on public exchanges, this entire sector seems to be priced like a clearance event. I don't believe calming every worry about the wider market—things beyond our control—falls to us, yet making sound strategic choices to secure the REIT's long-term expansion and the continued prosperity of the platform we've built at Chicago Atlantic is absolutely our duty. While the broader capital markets remain without greater steadiness and visibility, we've decided against seeking any debt or equity raise to fuel further REIT portfolio growth. Our standard has consistently been that fresh growth requires capital that adds value. Clearly, the only source of that today comes through our credit facility. So we're intensifying our push to grow the current facility by way of its accordion provision or to chase alternative growth avenues that boost book value. As our earnings release mentions, we've offered a set of projections for how we expect to perform during the year's second half. Right now we foresee Q3 and Q4, assuming no further expansion of the facility, resembling Q2 closely, with adjusted distributable earnings landing between $1 and $1.05 across the latter six months of 2022. For the entire 2022 year, that works out to $1.95 to $2. We'd likewise anticipate our dividend reaching no less than $0.47 per share in each of those quarters, and should that prove overly cautious, a special dividend might be needed at year's end to align our taxable income. Considering the conditions the market is showing us, we think this is the proper adjustment for the REIT; with just 17% to book value, we're carrying very little leverage, and our dividend has solid coverage. Our balance sheet is a fortress, and we're producing strong returns for shareholders. For the REIT, this is the correct step to take right now. Tony, go ahead and continue from here.

Tony Cappell

executive
#3

Thanks, John. Morning, everybody. 2022 turned out to be among the more turbulent stretches we've seen in some time, driven by macro factors such as inflation and climbing rates, plus considerable choppiness across the cannabis sector. To be more precise about the cannabis space, we've witnessed corrections relative to reality regarding how quickly regulatory changes have come and in terms of pricing pressure across numerous states, above all the biggest states out West. Given all those difficulties, it matters greatly that you build sturdy structures at the outset and also monitor loans closely throughout the life of the borrower connection. Lending to cannabis isn't high yield or liquid credit, where you purchase and dispose of paper from some ivory tower. This is direct lending, which calls for a substantial degree of oversight. A few illustrations of how we operate: liens on all assets that reach every asset the borrower holds past their real estate, pledges of stock covering every subsidiary they have, especially the ones holding the license, and securing some type of personal guarantee from most of our borrowers. When it comes to monitoring, we use tight financial covenants that deliver early signals, crafted to produce tabling events well before any meaningful drop in value occurs. We mandate monthly reporting along with covenant compliance from the vast majority of our borrowers, which lets us keep the freshest information, unlike others who may hold off until 30 days past quarter end before receiving their data. Our role as lenders is to underwrite risk. Having been one of the earliest in this space at any meaningful size, I think we've shown we understand how to do that and safeguard our capital. Demand for capital stays incredibly robust. We plan to satisfy that demand via the Chicago Atlantic platform. Once capital markets calm down, the REIT can right away boost its involvement in the top-tier origination platform we've built. At this point, Andreas will take us through our investments and capital plan.

Andreas Bodmeier

executive
#4

Thank you, Tony. Good morning to everyone. As of the thirtieth of June, total loan commitments in our portfolio had reached $357 million, spread across 22 portfolio companies. The weighted average yield to maturity stands at 17.7%, which is an increase from 17.2% as of March 31st. We originated $51 million during the quarter — that breaks down as $17 million to one new borrower, plus $34 million in incremental advances to borrowers we already had. One loan paid off at maturity over the quarter. Every loan is current and performing. Right now, 60% of our portfolio is floating rate, tied to the prime rate, which means we've been able to handle the effects of rising rates effectively. To echo what John stated at the start of this call, there's no demand issue in cannabis at present, whether we're discussing consumers or borrowers seeking growth capital. What we see as the core problem is that not enough capital is available in today's climate to finance incremental growth on terms that would boost book value; a dilutive capital raise — debt or equity — is something we've never considered. Our threshold has always been an accretive raise. If our stock has been falling because people anticipated we'd either lock in fixed interest rates at today's elevated levels with long-dated maturities, or issue equity at enormous discounts to prices seen through most of this year, purely to expand the portfolio, then hopefully what's been said today has clarified that. I'll hand things over to Lindsay now for our financials.

Lindsay Menze

executive
#5

Thanks, Andreas. Let's move to our financial results for Q2. As anticipated, we experienced the complete benefit from deploying our IPO proceeds and utilizing the credit facility during Q2. Net interest income rose sequentially, reaching $11.4 million, compared with $9.8 million in Q1. Total operating expenses came to $2.9 million for the quarter, including management and incentive fees of $1.2 million, G&A of $777,000, and professional fees of $744,000. Incentive and management fees rose sequentially, consistent with the higher interest income, whereas the remaining expenses increased versus the prior quarter, mainly because of non-recurring professional fees incurred in Q2. G&A remains inside our earlier guidance of $2.5 million-$3 million for the year. Under ASC 326, we raised our provision for expected credit losses by $1 million during Q2, equivalent to $0.06 per weighted average diluted common share. No specific factors affecting the credit quality of our borrowers caused the company's reserve to increase; instead, it's mainly from our quarterly reevaluation of overall current macroeconomic conditions. In setting this reserve, we observed that 95% of the portfolio is fully secured by real estate, while 5% has limited or no real estate collateral. As of June 30, 2022, our portfolio had average real estate collateral coverage of 1.9x. As Tony said earlier, real estate isn't our sole collateral. Every one of our loans has backing from borrower equity pledges as well as liens on all assets. Although the CECL reserve got added back when we calculated distributable earnings, just as we did in prior quarters, keep in mind that incentive fees are not being added back into either our distributable earnings calculation or our adjusted distributable earnings calculation, so that we give a transparent picture of our capacity to make dividend payments to shareholders. Once those items are taken into account, adjusted distributable earnings came to $0.50 per diluted share for Q2, which is a sequential increase from $0.45 in Q1. Book value on June 30 stood at $15.13 per common share. Operator, we are ready to begin the question-and-answer portion now.

Aaron Hecht

analyst
#6

Morning, everybody, and thanks for fielding my questions. John, you pointed out how volatile the capital markets have been out there, and how few options for creative capital are open to you folks. The debt markets — they've settled down somewhat across the past 2 weeks. With what's happened in the markets, are you any nearer to growing that credit facility now? Or is it more or less shut off? And second, are you looking at any alternative financing routes that are less conventional, perhaps preferreds or converts?

John Mazarakis

executive
#7

Let me take the second part first. No other options are on the table for us. Converts are completely off the table. We examined them. Honestly, they make no sense at all; as for the revolving facility, that's the finest capital source we can count on, in my view. Compared with our rates, it's really cheap. My thinking is we double down and pursue the remaining $35 million. Probably sometime in Q3, early Q4, we'll likely secure another $35 million under that facility, assuming markets on the debt side hopefully keep settling down.

Aaron Hecht

analyst
#8

Understood. When it comes to liquidity in the near term, before that $35 million comes in, I believe you've got commitments of a bit more than $25 million, and $26 million available from your current facility plus cash. How are you handling that liquidity over the short term? What amount is required simply to keep the business running day to day?

Tony Cappell

executive
#9

Aaron, oh, please continue, John.

John Mazarakis

executive
#10

No, no. I was gonna say, Tony, that's yours. Go ahead.

Tony Cappell

executive
#11

Right, Aaron, regarding that — a good chunk of it, as you're aware, when it comes to certain commitments, the credit facility includes some discretionary line items, so those exist in there. At present and for the foreseeable future, whatever demand would typically be allocated to the REIT has been absorbed entirely by the private fund, and the private fund has provided all the funding for it.

Aaron Hecht

analyst
#12

Aaron, that answers my question. All right, I appreciate it, and I'll get back in line.

John Mazarakis

executive
#13

John, thank you.

Gaurav Mehta

analyst
#14

Yeah, thanks, and good morning. You had a few remarks regarding satisfying demand via your Chicago Atlantic platform, and I believe you just mentioned the private fund. Could you give us a bit more detail on that front — the Chicago Atlantic platform, and the way you're handling demand?

Tony Cappell

executive
#15

Yeah. As for the private fund, it started up last year, and from then on it's been pulling in capital quite quickly. So, to offer an illustration, so far this year we've put roughly $120 million into deals, and that vehicle still holds a decent level of ongoing liquidity. As a result, the deals typically earmarked for the REIT — those that fully conform to real estate — are getting financed by way of the private fund. Usually, after things calm down, such deals will return to the REIT, since it has a preference when it comes to deals that fully conform to real estate.

Gaurav Mehta

analyst
#16

All right. My second question concerns your credit line, just so I understand correctly. Did you mention that you intend to grow the line by as much as another $35 million?

Tony Cappell

executive
#17

That's right. Our current credit facility includes an accordion provision that takes it from $65 million up to $100 million, contingent on syndication. Right now, we're widening the range of alternatives we're considering in order to add additional banks as co-lenders and participants in that facility.

Gaurav Mehta

analyst
#18

Alright, thanks.

Mark Smith

analyst
#19

Hey there, everyone. I'm hoping to get a wider view of what's happening across the sector. So, what are you observing on a daily basis in the markets you serve? Has there been further deterioration that spilled in from those larger states? Or does it feel like we've hit the floor? Any perspective on where things stand would be appreciated.

John Mazarakis

executive
#20

Appreciate the question. John Mazarakis here. The notable squeeze we're seeing is mostly concentrated out west — California, Colorado, Oregon, and Washington State. Clearly, when it comes to certain medical markets back east, there's been a modest stabilization. Growth has been fairly constrained in places such as PA. Michigan caught us off guard. In my view, Michigan is a genuinely robust market. The cannabis business there is doing quite well, it has expanded without interruption, and that expansion continues. Massachusetts likewise caught us off guard, despite having what you could call a mixed setup — part oligopoly, part fully competitive market, depending on your lens. Massachusetts has been putting up solid numbers. Naturally, New York is in the process of launching. New Jersey has essentially hit it out of the park. It's common knowledge that New Jersey has done remarkably well. Delaware was unexpected. Our expectation was that Delaware would go rec. Recreational sales passed both the Senate and the House. Sadly, the governor struck down that bill. Despite holding supermajority power, they chose to side with the governor, so Delaware never went rec. Among other states in the process of launching, Ohio handed out several additional licenses. Ohio has us quite enthusiastic. We believe it will do very well over the long haul. PA is experiencing some squeeze, yet it remains a medical market with enormous potential. Florida, I'd say, is a massive triumph. That said, from the medical side, it might be approaching its ceiling before recreational sales begin. That's roughly a wide-angle snapshot of how I read the marketplace. In my view, the medical markets, even when they're sort of leveling off, still have potential upside of perhaps 3-5x on the top line and perhaps 5-10x on the bottom line once recreational sales begin. When it comes to the medical states, we remain quite enthusiastic. We've witnessed this repeatedly in Illinois, Massachusetts and Michigan. Each time a state transitions from medical to rec, the top line and the bottom line experience, well, a significant multiplier effect. That sums up how I see the industry's overall condition.

Mark Smith

analyst
#21

Great. In a similar vein, you touched on a few specific states, but do you have any opinions or fresh information regarding the regulatory landscape at the federal level?

John Mazarakis

executive
#22

My view is that federal relief of some kind could catch us off guard this time around. I have been incorrect about this so many times that I would rather not even attempt to give an answer. Plenty of people are saying something is going to happen. We are not counting on it, though it would be a net positive. My expectation is that it would reduce what we pay for capital. It would draw additional capital into the marketplace. I believe we have created an outstanding brand, and that expansion will benefit us.

Mark Smith

analyst
#23

Excellent. Thank you, guys.

John Mazarakis

executive
#24

Thank you.

Harrison Vivas

analyst
#25

Great. Pardon me. Thank you. I really appreciate you fielding my questions. I was sort of hoping to circle back around to what Mark asked, though perhaps put it a different way when it comes to the portfolio. Your portfolio's risk rating has ticked up somewhat. I realize that may not mirror how the underlying names are actually performing. So I suppose what I'm asking is: which geographies are you becoming more worried about, and in what way does that shape how you assess risk across the portfolio? Thank you.

John Mazarakis

executive
#26

Lindsay, do you want to handle that one?

Lindsay Menze

executive
#27

Absolutely, John. Yeah, I believe that's a solid observation about how risk ratings throughout our portfolio have gone up. This has nothing to do with a particular borrower or any individual problem tied to one, but instead stems from broader market circumstances involving interest rates and spreads. I mean, as John brought up before, it's sort of a tale of two cities. We've seen negative GDP growth for 2 straight quarters. Yet cannabis nationally expanded 30% during the first half of the year. A large portion of that is driven by markets shifting from medical to recreational. On the whole, we consider the credit quality of our borrowers to be strong in the states where we operate, and we simply don't wish to overlook what's happening in the wider market, inside our portfolio.

Harrison Vivas

analyst
#28

All right. So it's genuinely wide-ranging rather than actually tied to a particular market — I just want to make sure?

Lindsay Menze

executive
#29

Exactly right. Yes.

John Mazarakis

executive
#30

That's right.

Harrison Vivas

analyst
#31

All right, got it. So when we look at New York, it seems like the rules aren't really going to work in favor of the well-established MSOs. As you weigh that as a possible chance, what factors matter to you when it comes to the kind of borrower, and how large do you figure that state's opportunity could be?

John Mazarakis

executive
#32

New York is going to do extremely well, in my view; it's an enormous state. There's a lot of talk that it could end up the largest state, perhaps even overtaking California. We're aware that a significant, considerable illicit market exists in New York, and it's basically running out in plain sight. To give you a straight answer, I'd say that any fragmentation inside the state works to our advantage as lenders. It pushes our, well, risk, most likely. The risk stays the same since New York is going to be a terrific market, yet the return comes in much higher within the middle market. Any form of fragmentation helps us as providers of credit.

Harrison Vivas

analyst
#33

All right, got it. This will be my final question. Tony, you mentioned that roughly 60% of the portfolio consists of floating rate exposure. So how does that compare against the targets we set internally? When you're putting on new loans, I'd assume the emphasis is on floating rate deals, but how do you weigh your activity between floating and fixed rate?

Tony Cappell

executive
#34

Sure. Essentially all of what we've completed over the past several months has been floating, and all of what we intend to complete going forward is going to be floating. If anything, I'd expect that figure to rise, as either new loans get repaid or new loans get repaid and closed out. I think it's simply one of those areas where we hold a firmer stance on the front end. In my view, 60% serves as a solid reference point, though we intend to keep growing that figure over an extended time frame.

Harrison Vivas

analyst
#35

Understood. Thanks very much. I'll jump back in the queue.

Operator

operator
#36

That's all the questions we have right now. Today's earnings call ends here. We appreciate your participation. You're free to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Chicago Atlantic Real Estate Finance, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to Chicago Atlantic Real Estate Finance, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Chicago Atlantic Real Estate Finance, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.